Source: World Health Organization (WHO) - Eswatini |

Eswatini achieves the 95-95-95 Human immunodeficiency viruses (HIV) treatment target - a decade ahead of 2030 goal

Among the key milestones that WHO supported in the Eswatini HIV response is the establishment of the antiretroviral therapy (ART) program in 2003 to improve access to treatment and care services

The Kingdom of Eswatini has made major strides in the HIV response with the goal of ending AIDS as a public health threat by 2030. Eswatini, being the first African country to achieve and surpass the 95-95-95 global HIV treatment targets in 2020, has 94% of adults (15 years and older)…

World Health Organization (WHO) - Eswatini
Source: World Health Organization (WHO) - Eswatini |

Intensified efforts to maintain a Polio free Eswatini

The purpose of the POSE was to test Eswatini’s operational readiness to respond to a polio outbreak

Eswatini has joined countries like Botswana, Mozambique, and Malawi in intensifying efforts to protect more people from polio. Following the finalisation of the National Polio Preparedness and Response Plan, the country went on to conduct a Polio Outbreak Simulation Exercise (POSE). This was through a two-day Tabletop Exercise (TTX) conducted…

World Health Organization (WHO) - Eswatini
Source: World Health Organization (WHO) - Eswatini |

Eswatini hosts the 15th biennial East, Central and Southern Africa College of Nursing conference

The conference was officially opened by the World Health Organization (WHO) Director-General Dr. Tedros Ghebreyesus

The Kingdom of Eswatini has once again hosted the East, Central, and Southern Africa College of Nursing (ECSACON) delegates for the 15th Biennial Scientific Conference and the 7th Quadrennial General Assembly. The conference kicked off on a high note in Manzini on 13 September 2022, with delegates from 16 Eastern,…

Source: World Health Organization (WHO) - Eswatini |

Why Shorter tuberculosis (TB) Regimen is the Most Preferred by Patients in Eswatini

In Eswatini, most patients are adhering to the oral short course therapy (OSCT) since they are tolerable with less side effects

Siphephelosethu Ntjangase is a 21-year-old university student from Hluti village in the Shiselweni region who suffers from pulmonary drug resistant tuberculosis (DR-TB).  In October 2021 before getting checked, he noticed that he was losing weight, sweating at night and had a persistent cough that had lasted over a year. From…